Elixir Medical has unveiled the DynamX® BTK System, a groundbreaking implant designed to treat narrowed or blocked vessels below-the-knee (BTK) in patients diagnosed with chronic limb-threatening ischaemia (CLTI).
The DynamX Bioadaptor platform is a groundbreaking medical technology aiming to set a new standard for vascular interventions. It uniquely supports vessels during the healing phase, subsequently unlocking and "uncaging" the vessel while providing dynamic support to restore vessel function and maintain an open lumen.
The DynamX Bioadaptor is the first implant technology designed to unlock, uncage, and restore vessel motion and function after intervention. It establishes a new standard of care for vascular interventions, addressing both coronary and peripheral artery disease.
This bioadaptor offers a promising approach in BTK revascularization, providing significant acute lumen gain and sustaining it over time—a common challenge in existing therapies. Additionally, it restores vessel motion and function, promotes adaptive remodelling, enhances vessel compliance, pulsatility, and increases blood flow volume.
Peripheral arterial disease (PAD) affects over 200 million people globally, with its severe form, CLTI, posing significant risks to life and limb. Without revascularization, CLTI often leads to major amputations.
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for addressing narrowed or obstructed vessels below-the-knee (BTK) in patients suffering from chronic limb-threatening ischaemia (CLTI).
